38,091 Shares in Bristol Myers Squibb Company $BMY Bought by Paralel Advisors LLC

Paralel Advisors LLC purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 38,091 shares of the biopharmaceutical company’s stock, valued at approximately $2,195,000.

A number of other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC increased its position in Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares during the last quarter. Sivia Capital Partners LLC raised its stake in Bristol Myers Squibb by 59.4% during the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 2,786 shares in the last quarter. United Bank lifted its position in Bristol Myers Squibb by 15.0% during the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after purchasing an additional 3,277 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter worth $221,000. Finally, Nebula Research & Development LLC purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter worth $405,000. Institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on BMY shares. Bank of America reduced their price objective on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. Cantor Fitzgerald reissued a “neutral” rating and set a $59.00 target price (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Royal Bank Of Canada raised their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. UBS Group lowered shares of Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 5th. Finally, Truist Financial reiterated a “buy” rating and set a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Bristol Myers Squibb presently has a consensus rating of “Moderate Buy” and an average price target of $66.06.

Bristol Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $65.54 on Friday. The firm has a 50 day moving average of $60.35 and a 200 day moving average of $59.31. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The company has a market capitalization of $133.88 billion, a price-to-earnings ratio of 14.44, a price-to-earnings-growth ratio of 0.18 and a beta of 0.22. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same quarter in the previous year, the firm earned $1.46 earnings per share. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, sell-side analysts predict that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.8%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is presently 55.51%.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a collaboration with Chai Discovery to use artificial intelligence for antibody discovery. The partnership could improve the speed and efficiency of developing new therapies, although financial terms and the near-term earnings impact were not disclosed. Chai Discovery collaboration with Bristol Myers Squibb
• Positive Sentiment: An update on the Phase 1 study of navlimetostat indicates continued progress in Bristol Myers Squibb’s early-stage pipeline. The program remains experimental, so any commercial benefit is still distant and uncertain. Bristol Myers Squibb navlimetostat study update
• Positive Sentiment: Hematogenix said its minimal residual disease assay supported the FDA’s accelerated approval of Bristol Myers Squibb’s ZENBEXUS™, described as the first approved CELMoD therapy for multiple myeloma. The approval could expand the company’s oncology opportunity, though accelerated approvals typically require confirmatory evidence. Hematogenix assay and ZENBEXUS approval
• Positive Sentiment: Unusually heavy call-option activity, with 55,757 calls purchased—more than double the average volume—signals increased speculative interest in BMY. Options activity is not confirmation of a sustained rally and can increase volatility.
• Positive Sentiment: Analyst coverage continues to characterize BMY as an attractive value stock, supported by its relatively low valuation and income potential. A separate comparison also frames Bristol Myers Squibb as a potential bargain versus AstraZeneca, though these are opinion-based assessments. Zacks BMY value-stock analysis
• Neutral Sentiment: Articles discussing a covered-call strategy emphasize income generation rather than a bullish outlook for capital appreciation. The strategy may appeal to yield-focused investors but can limit upside if the shares rise sharply. Bristol Myers Squibb options income strategy
• Neutral Sentiment: A report on Aktis Oncology, which has attracted interest from Bristol Myers Squibb and other large pharmaceutical companies, highlights potential future deal activity but does not announce a transaction or create an immediate financial impact for BMY. Pharmaceutical interest in Aktis Oncology

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.